Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363024 | 0.81 | KDM4E (0.45) | KDM4EGLARCE1TAAR1DRD2 | |
| SCHEMBL28494818 | 0.78 | KDM4E (0.49) | KDM4EGLARCE1DAOTAAR1 | |
| SCHEMBL990162 | 0.72 | KDM4E (0.72) | KDM4EGLARCE1PKM | |
| SCHEMBL3654274 | 0.72 | KDM4E (0.61) | KDM4EGLARCE1PKMMAOB | |
| SCHEMBL7542282 | 0.70 | KDM4E (0.44) | KDM4EGLARCE1TAAR1MAOB | |
| SCHEMBL1363642 | 0.69 | NOS3 (0.44) | KDM4EGLARCE1DAOTAAR1 | |
| SCHEMBL945359 | 0.69 | KDM4E (0.48) | KDM4EGLARCE1TAAR1DRD2 | |
| SCHEMBL12200072 | 0.68 | KDM4E (0.58) | KDM4EGLARCE1PPARDPPARA | |
| Acetic Acid SCHEMBL2478031 | 0.68 | KDM4E (0.67) | KDM4EGLARCE1PPARDPPARA | |
| SCHEMBL990879 | 0.68 | KDM4E (0.64) | KDM4EGLARCE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| CN-101646668-A | Heterocycles as orexin antagonists | HOFFMANN LA ROCHE CH | 2010-02-10 | — | — | CN | disclosed |
| EP-2144906-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, HRH3 | KDM4E 2391/4885GLA 4689/4885RCE1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.